Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This authoritative book covers the fundamentals relating to the science and technology of drug delivery.  The book is written at a level that is understandable to those entering the field and who are not familiar with its common phrases or complex terms.  It is a book that provides a simple encapsulation of concepts and expands on them using a building block approach to each subject, starting at a basic level and building to extend the readers knowledge and application of the subject.  In each chapter the basic concept is explained as simply and clearly as possible without a great deal of detail, then in subsequent sections additional material is introduced in order to build up the reader’s understanding and comprehension of the subject matter.   The book comprises several Parts.  The first part covers the fundamentals of drug delivery, the second covers delivery materials, the third deals with delivery systems (both temporal and spatial) and the fourth introduces the reader to some clinical applications of drug delivery. The book ends with a future outlook chapter in which prospects for the field are envisioned.   This book will be indispensable to scientists interested in the science and technology of drug delivery and be essential for those developing delivery systems designed to improve the clinical performance of a drug.   Professor Juergen Siepmann is Professor of Pharmaceutics at the College of Pharmacy, Université Lille Nord de France, Lille, France. He studied pharmacy and received his doctoral degree from the Freie Universitaet Berlin, Berlin, Germany, in 1999. His research focuses on the elucidation of the underlying mass transport phenomena in controlled drug delivery systems. Prof. Siepmann is reviews editor of the International Journal of Pharmaceutics and president of APGI (French Association of Pharmaceutical Technology). Since 2010 he is heading the INSERM (French National Institute of Health and Medical Research) research group “Controlled Drug Delivery Systems and Biomaterials”.     Ronald A. Siegel, Sc.D., is Professor of Pharmaceutics and Biomedical Engineering at the University of Minnesota.  He received his doctoral degree from MIT under the direction of Prof. Robert Langer in 1984, and taught at the University of California, San Francisco until 1998, when he moved to Minnesota.  Professor Siegel is Fellow of the Controlled Release Society (CRS), the American Association of Pharmaceutical Scientists, and the American Institute of Medical and Biological Engineering.  He was president of CRS from 1997-1998.  His present research interests include hydrogels, block polymers, microfabricated sensors and drug delivery systems, and mathematical modeling of transport.     Michael J. Rathbone is Associate Professor of Pharmaceutics at the School of Pharmacy, Griffith University, Australia.  Dr. Rathbone’s research interests are in the modified delivery of bioactives to the mouth, polymeric delivery systems and long acting veterinary drug delivery systems.  He is a Fellow of the Controlled Release Society (CRS) and received the CRS Distinguished Service Award in 2006.  He has edited or co-edited many books in the fields of modified release drug delivery, oral mucosal drug delivery and veterinary drug delivery.

Drug delivery systems. --- Drugs -- Controlled release. --- Drugs. --- Drugs --- Drug delivery systems --- Drug Therapy --- Investigative Techniques --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Therapeutics --- Drug Delivery Systems --- Methods --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Controlled release --- Controlled release. --- Delayed-action drugs --- Prolonged-action drugs --- Slow-release drugs --- Sustained-release drugs --- Timed-release drugs --- Medicine. --- Pharmacy. --- Pharmacology. --- Biochemistry. --- Biomedicine. --- Pharmacology/Toxicology. --- Biochemistry, general. --- Biological chemistry --- Chemical composition of organisms --- Organisms --- Physiological chemistry --- Biology --- Chemistry --- Medical sciences --- Drug effects --- Medical pharmacology --- Chemicals --- Chemotherapy --- Pharmacy --- Medicine --- Materia medica --- Pharmacology --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Pathology --- Physicians --- Composition --- Physiological effect --- Controlled release preparations --- Dosage forms --- Toxicology. --- Poisoning --- Poisons --- Toxicology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmacotechnology. Preparations --- Drugs --- Médicaments --- Médicaments-retard --- Dosage forms --- Controlled release --- Formes pharmaceutiques --- Technology, Pharmaceutical --- Biopharmaceutics --- Dosage Forms --- Drug Administration Routes. --- Technology, Pharmaceutical. --- Pharmaceutic Technology --- Pharmaceutical Technology --- Pharmacy Technology --- Technology, Pharmaceutic --- Technology, Pharmacy --- Drug Industry --- Administration Routes, Drug --- Administration Route, Drug --- Drug Administration Route --- Route, Drug Administration --- Routes, Drug Administration --- Drug Delivery Systems --- Chemistry, Pharmaceutical --- Médicaments --- Médicaments-retard --- Drug Administration Routes --- Compounding, Drug --- Dosage forms of drugs --- Drug compounding --- Pharmaceutical compounding --- Pharmaceutical dosage forms --- Drug delivery systems --- Delayed-action drugs --- Prolonged-action drugs --- Slow-release drugs --- Sustained-release drugs --- Timed-release drugs --- Controlled release preparations --- Geneesmiddelen. Posologie. --- Médicaments. Posologie. --- Geneesmiddelen. --- Drugs - Dosage forms --- Drugs - Controlled release --- Controlled-release drug delivery systems --- Encapsulation --- Liposomes --- Particles --- Polymers

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical  needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all.  Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

Antipsychotic agents -- Therapeutic use. --- Antipsychotic drugs -- Controlled release. --- Injections. --- Antipsychotic drugs --- Tranquilizing Agents --- Schizophrenia and Disorders with Psychotic Features --- Therapeutics --- Psychotropic Drugs --- Central Nervous System Depressants --- Mental Disorders --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Central Nervous System Agents --- Physiological Effects of Drugs --- Psychiatry and Psychology --- Pharmacologic Actions --- Therapeutic Uses --- Chemical Actions and Uses --- Chemicals and Drugs --- Antipsychotic Agents --- Drug Therapy --- Psychotic Disorders --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Antipsychotic drugs. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Medicine. --- Pharmacy. --- Neurosciences. --- Pharmacology. --- Behavioral sciences. --- Proteins. --- Neurobiology. --- Biomedicine. --- Pharmacology/Toxicology. --- Receptors. --- Behavioral Sciences. --- Psychotropic drugs --- Psychoses --- Chemotherapy --- Toxicology. --- Cell receptors. --- Animal behavior. --- Chemistry --- Medicine --- Drugs --- Materia medica --- Pharmacology --- Animals --- Animals, Habits and behavior of --- Behavior, Animal --- Ethology --- Animal psychology --- Zoology --- Ethologists --- Psychology, Comparative --- Neurosciences --- Cell membrane receptors --- Cell surface receptors --- Receptors, Cell --- Binding sites (Biochemistry) --- Cell membranes --- Proteins --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Chemicals --- Poisoning --- Poisons --- Behavior --- Toxicology --- Proteins . --- Proteids --- Biomolecules --- Polypeptides --- Proteomics --- Drug effects --- Medical pharmacology --- Pharmacy --- Physiological effect